Loading...

PODCAST

VJHemOnc Podcast

The Video Journal of Hematology and Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a

health & fitness medicine

All Episodes

25:04

IMS 2026 highlights: advances in multiple myeloma...

VJHemOnc Podcast ·

2026/10/09

In this episode of the VJHemOnc podcast, experts discuss key advances in multiple myeloma presented at the 23rd Annual Meeting and Exposition of the International Myeloma Society (IMS 2026) in Glasgow, UK. Pieter Sonneveld, MD, PhD, Erasmus MC, Rotterdam, Netherlands, reviews long-term outcomes from the Phase III PERSEUS trial (NCT03710603), while Zachary Avigan, MD, Icahn School of Medicine at Mount Sinai, New York, NY, explores treatment cessation and the potential for cure. Rakesh Popat, MBBS,

en-gb

22:04

Personalizing BTK Inhibitor Therapy in CLL: from...

VJHemOnc Podcast ·

2026/10/02

This VJHemOnc podcast explores how BTK inhibitor therapy can be personalized for patients with chronic lymphocytic leukemia (CLL), considering disease biology, patient characteristics and treatment goals.Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses frontline treatment selection, molecular risk and factors influencing BTK inhibitor choice, while Florian Simon, MD, University Hospital Cologne, Cologne, Germany, examines cardiovascular toxicity and treatment considerations

en-gb

22:32

Using BTK inhibitors in lymphoma: practical...

VJHemOnc Podcast ·

2026/09/11

This episode of the VJHemOnc podcast, featuring Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, focuses on the practical use of BTK inhibitors (BTKis) in non-Hodgkin lymphoma (NHL). Dr Kamdar begins by discussing which factors guide patient selection for BTKi therapy and outlines how to choose among available agents. She then shares valuable insights on toxicity management, approaching patients with cardiovascular comorbidities, and monitoring treatment response and progression

en-gb

24:21

AAV gene therapy in hemophilia: progress, challenges...

VJHemOnc Podcast ·

2026/09/03

This VJHemOnc podcast explores the evolving role of gene therapy in hemophilia, focusing on the challenges of AAV-based approaches and the development of next-generation strategies.Radek Kaczmarek, PhD, Indiana University School of Medicine, Indianapolis, IN, discusses the limitations of AAV gene therapy in hemophilia A, including factor VIII engineering, durability, and liver toxicity. He also examines potential malignancy risks associated with AAV integration and the importance of long-term

en-gb

18:12

Clinical considerations in MCL management: frailty...

VJHemOnc Podcast ·

2026/08/26

This VJHemOnc podcast explores the evolving management of mantle cell lymphoma (MCL), from assessing patient fitness to sequencing therapy after BTK inhibitor progression. Tycel Phillips, MD, FASCO, City of Hope, Duarte, CA, and Yasmin Karimi, MD, University of Michigan, Ann Arbor, MI, discuss assessing fitness and frailty, while Craig Portell, MD, University of Virginia, Charlottesville, VA, outlines the multidisciplinary approach to MCL care. Nirav Shah, MD, Medical College of Wisconsin,

en-gb

24:18

Sequencing therapies in multiple myeloma: navigating...

VJHemOnc Podcast ·

2026/08/24

This VJHemOnc podcast explores the evolving treatment landscape in multiple myeloma, focusing on treatment selection and sequencing across the disease course. Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses shared decision-making in frontline treatment, while Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, explores sequencing CAR T-cell therapies and bispecific antibodies, including the choice between BCMA- and GPRC5D-directed approaches. Rahul Banerjee,

en-gb

23:31

The evolving treatment landscape in ALL: the growing...

VJHemOnc Podcast ·

2026/08/14

There has been a significant shift in the treatment of acute lymphoblastic leukemia (ALL), driven by the emergence of novel immunotherapies. In this episode, leading experts explore how these advances are changing the treatment landscape and where the field is headed next. First, Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, outlines emerging treatment strategies for ALL and highlights the potential to reduce reliance on intensive chemotherapy by integrating novel therapies

en-gb

19:30

Precision medicine in MDS: tailoring treatment...

VJHemOnc Podcast ·

2026/08/07

This VJHemOnc podcast explores how precision medicine is reshaping the management of myelodysplastic syndromes (MDS). Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses whole genome sequencing, patient selection for venetoclax-based therapy, and the future of precision medicine following the VERONA trial (NCT04401748). Pinkal Desai, MD, MPH, Weill Cornell Medicine, New York, NY, reviews the evolving role of luspatercept, while Sophie Park, MD, PhD, CHU

en-gb

24:15

The current and future role of BTK inhibitors across...

VJHemOnc Podcast ·

2026/07/23

This episode of the VJHemOnc podcast explores the current and future role of BTK inhibition across several non-Hodgkin lymphoma (NHL) subtypes. First, Charalampia Kyriakou, MD, PhD, University College London Hospitals NHS Trust (UCLH), London, UK, Steven Treon, MD, PhD, FRCP, Dana-Farber Cancer Institute, Boston, MA, and Anna Maria Frustaci, MD, Niguarda Hospital, Milan, Italy, provide insight into the established role of BTK inhibitors (BTKis) in Waldenström's macroglobulinemia (WM). Following

en-gb

17:39

The diagnosis and management of hematologic...

VJHemOnc Podcast ·

2026/07/16

In this episode of the VJHemOnc podcast, Daan Dierickx, MD, PhD, KU Leuven and University Hospitals Leuven, Leuven, Belgium, shares insight into the diagnosis and management of hematologic malignancies during pregnancy. Dr Dierickx comments on common misconceptions clinicians may have when treating this patient population and outlines key principles and factors that guide clinical decisions for pregnant patients to optimize outcomes for both the mother and the baby. He then discusses the current

en-gb

19:13

Hodgkin lymphoma in 2026: frontline strategies,...

VJHemOnc Podcast ·

2026/07/10

This VJHemOnc podcast explores the latest advances in Hodgkin lymphoma, from evolving frontline treatment strategies to emerging approaches in relapsed and refractory disease. Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the final three-year results from the AVENUE study (NCT03617666) and the role of circulating tumor DNA (ctDNA) in guiding treatment de-escalation. Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, compares

en-gb

19:45

Sequencing BTK inhibitor therapy in CLL: treatment...

VJHemOnc Podcast ·

2026/06/30

This podcast explores sequencing strategies and treatment considerations for BTK inhibitors in chronic lymphocytic leukemia (CLL). Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses treatment options following covalent BTK inhibitor therapy, including venetoclax-based regimens and non-covalent BTK inhibitors. Gianluca Gaidano, MD, PhD, University of Eastern Piedmont, Vercelli, Italy, examines treatment selection after BTK inhibitor therapy, the improved safety profile of

en-gb

19:53

Precision medicine in AML: from targeted therapy to...

VJHemOnc Podcast ·

2026/06/22

This podcast explores the evolving role of precision medicine in acute myeloid leukemia (AML), highlighting advances in molecular profiling, targeted therapies, measurable residual disease (MRD) assessment, and transplantation. Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses the Phase I/II KOMET-007 study (NCT05735184) evaluating ziftomenib in combination with intensive chemotherapy for newly diagnosed NPM1-mutated or KMT2A-rearranged AML, while Amir Fathi,

en-gb

20:35

MPNs in focus: disease progression, risk assessment,...

VJHemOnc Podcast ·

2026/06/15

This VJHemOnc podcast explores how advances in disease biology, risk stratification, and therapeutic development are reshaping the management of myeloproliferative neoplasms (MPNs). Stephen Oh, MD, PhD, Washington University School of Medicine, St. Louis, MO, discusses mechanisms of disease progression, the DUSP6-RSK1 signaling pathway as a therapeutic target, and the ongoing debate around early versus late intervention in MPNs. Hélène Gleitz, PhD, Erasmus MC, Rotterdam, Netherlands, shares insights

en-gb

19:22

The evolving role of cellular therapies and T-cell...

VJHemOnc Podcast ·

2026/05/29

This VJHemOnc podcast explores emerging cellular therapies and T-cell engagers in non-Hodgkin lymphoma (NHL). Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, is joined by Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Michael Jain, MD, PhD, Moffitt Cancer Center, Tampa, FL, to discuss novel cellular therapy strategies, including NK-cell therapies, allogeneic CAR T-cells, and in vivo CAR approaches. The panel highlights early clinical data with

en-gb

20:02

Multiple myeloma in 2026: MRD, BCMA therapies, CAR-T,...

VJHemOnc Podcast ·

2026/05/22

This VJHemOnc podcast explores how evolving treatment strategies, immunotherapies, and MRD-driven approaches are reshaping the management of multiple myeloma and precursor disease. Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses early intervention strategies in smoldering myeloma and presents findings from the CAR-PRISM study (NCT05767359) evaluating cilta-cel in high-risk smoldering disease. Kwee Yong, MD, PhD, FRCP, FRCPath, University College London, London, UK, highlights

en-gb

25:13

Dual-targeting CAR T-cell therapies in LBCL:...

VJHemOnc Podcast ·

2026/05/15

This VJHemOnc podcast features a roundtable discussion from the 8th International Workshop on CAR-T and Bispecifics (iwCAR-T) 2026 on the evolving role of dual-targeting CAR T-cell therapies in large B-cell lymphoma (LBCL). Gloria Iacoboni, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, is joined by Saurabh Dahiya, MD, FACP, Stanford University School of Medicine, Stanford, CA, Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, Krish Patel, MD, Sarah Cannon

en-gb

17:27

Advances in gene-based therapies for SCD and...

VJHemOnc Podcast ·

2026/05/08

This VJHemOnc podcast explores the latest advances in gene-based therapies for sickle cell disease (SCD) and thalassemia, highlighting progress in patient access, selection, treatment delivery, and clinical outcomes. Sunil Gupta, MD, FRCP, FRCPath, MBA, Lewisham and Greenwich NHS Trust, London, UK, discusses expanding access to gene therapy for patients with SCD, while Alexander Ngwube, MD, Baylor College of Medicine, Houston, TX, shares insights into real-world patient selection and

en-gb

25:04

The evolving role of BTK inhibitors in CLL

VJHemOnc Podcast ·

2026/05/01

en-gb

19:10

Adverse events in the post-CAR T-cell therapy...

VJHemOnc Podcast ·

2026/04/24

In this episode of the podcast, we focus on adverse events (AEs) and toxicities in the post-CAR T-cell therapy setting. First, Marion Subklewe, MD, Ludwig Maximilians University of Munich, Munich, Germany, outlines the main factors contributing to the observed reduction in the incidence of higher-grade CRS and ICANS following CAR-T. Following this, Eleftheria Kampouri, MD, University of Lausanne, Lausanne, Switzerland, shares insight into infection prevention and antibiotic use in febrile patients,

en-gb

329 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

Healthy Chat

DR ALI BANIHAMOUR

Dingue ‐ RTS

RTS - Radio Télévision Suisse

Raw Reality

TORISSTORY & FITWITHLILY

The Jordan Syatt Podcast

Jordan Syatt